This episode features Rami Rahal, an investor at a leading biotech investment firm with a background spanning genetic research, drug discovery, and successful program development through approval. Having operated on both the development and investment sides, he brings a rare, practical lens on what makes a biotech company fundable.

Key takeaways:

•  Milestones define your valuation, and your credibility. They must be grounded in cross-functional alignment and achievable timelines.
• Regulatory leadership is a strategic differentiator. When positioned at the C-suite level, regulatory shapes the development path, anticipates hurdles, and enables efficient, high-quality execution.
• Confidence comes from clarity on risk. Transparent, well-articulated risks, and plans to manage them, build far more trust than over-optimized narratives.
• Execution is what investors underwrite. Enrollment, data generation, and regulatory sequencing are the true drivers of value inflection.
• Experience changes outcomes. Teams that integrate experienced regulatory leadership early are better positioned to deliver on what they promise.

For biotech executives, this highlights the importance of elevating regulatory into a core strategic voice strengthens both the development plan and the investor narrative.

Listen to the episode to hear directly from an investor on what builds and breaks confidence.